Abstract
Transfusion-dependent E-Beta (EB) thalassemia is one of the major causes of hereditary hemoglobinopathies in India. Hydroxyurea has been tried for HbF induction and amelioration of the transfusion frequency in EB thalassemia. The primary objective of this retrospective study, conducted between January 2017 and December 2018, was to determine the efficacy of thalidomide in reducing transfusion frequency in patients with EB thalassemia who have failed a reasonable trial of hydroxyurea. Of the 21 patients studied, 15 (71.4%) attained transfusion independence (complete responders) and 1 (4.7%) attained partial response (50% decrease in transfusion requirement) while 5 (23.9%) were non-responders. 12 patients attained their response within 1 month, 2 patients achieved within 1–3 months, and 1 patient beyond 3 months. Median time to transfusion independence in complete responders was 1 month. The median time on thalidomide for the complete responders and partial responders was 16.48 months. No major grade 3/4 toxicities were documented. This approach needs larger randomised controlled studies. Thalidomide is a safe and effective strategy at reducing or abrogating transfusion requirement in patients with EB thalassemia. This approach requires further testing in systematic clinical trials.
This is a preview of subscription content, log in via an institution to check access.
References
Olivieri NF, Pakbaz Z, Vichinsky E (2011) Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian J Med Res 134:522–531
Weatherall DJ, Clegg JB (2001) Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 79:704–712
Makala LH, Torres CM, Clay EL, Neunert C, Betty SP (2014) Fetal hemoglobin induction to treat b-hemoglobinopathies: from bench to bedside. J Hematol Transfus 2:1–12
Yang CS, Kim C, Antaya RJ (2015) Review of thalidomide use in the pediatric population. J Am Acad Dermatol 72:703–711
Ren Q, Zhou Y-L, Wang L, Chen Y-S, Ma Y-N, Li P-P, Yin X-L (2018) Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Ann Hematol 97:1933–1939
Chen J, Zhu W, Cai N, Bu S, Li J, Huang L (2017) Thalidomide induces haematologic responses in patients with β-thalassaemia. Eur J Haematol 99:437–441
Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP, E/beta Thalassaemia Study Group (2005) Fetal haemoglobin augmentation in E/beta0 thalassaemia: clinical and haematological outcome. Br J Haematol 131:378–388
Biswas S, Nag A, Ghosh K, Ray R, Roy K, Bandyopadhyay A, Bhattacharyya M (2019) Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia. Ann Hematol. https://doi.org/10.1007/s00277-018-3536-x
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nag, A., Radhakrishnan, V.S., Kumar, J. et al. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. Indian J Hematol Blood Transfus 36, 399–402 (2020). https://doi.org/10.1007/s12288-020-01263-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-020-01263-2